Compounds > diltiazem
Page last updated: 2024-08-23

diltiazem and cilostazol

diltiazem has been researched along with cilostazol in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Erkalp, K; Inan, B; Küçükgergin, C; Nurten, A; Seçkin, Ş; Sönmez Ergün, S; Zengin Türkmen, A; Ziyade, S1

Reviews

1 review(s) available for diltiazem and cilostazol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for diltiazem and cilostazol

ArticleYear
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
MICE models: superior to the HERG model in predicting Torsade de Pointes.
    Scientific reports, 2013, Volume: 3

    Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Cilostazol for intermittent claudication.
    The Medical letter on drugs and therapeutics, 1999, May-07, Volume: 41, Issue:1052

    Topics: Cilostazol; Diltiazem; Drug Interactions; Erythromycin; Humans; Intermittent Claudication; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Vasodilator Agents

1999
Effects of Cilostazol and Diltiazem Hydrochloride on Ischemia-Reperfusion Injury in a Rat Hindlimb Model.
    The heart surgery forum, 2017, Apr-29, Volume: 20, Issue:2

    Topics: Animals; Calcium Channel Blockers; Cilostazol; Diltiazem; Disease Models, Animal; Drug Therapy, Combination; Hindlimb; Male; Rats; Rats, Wistar; Reperfusion Injury; Tetrazoles; Treatment Outcome; Vasodilator Agents

2017